Cyclophosphamide for GVHD Continues to Extend Stem-Cell Transplant Eligibility

(MedPage Today) — Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall survival (OS) of about 80% with post-transplant cyclophosphamide (PTCy)-based prophylaxis for graft-versus…